01 July 1996
Caffeine clearance in patients with primary biliary cirrhosis
Frantisek Perlik, Martin Gilar, Marie BrodanovaMed Sci Monit 1996; 2(4): CR457-460 :: ID: 499946
Abstract
The clinical value and the sensitivity of saliva caffeine clearance measurement was evaluated as an indicator of liver metabolic capacity in patients with primary biliary cirrhosis (PBC). Saliva test was performed in 12 female patients with PBC and 8 healthy female volunteers. After a 48 hour caffeine exclusion period two doses of 140 mg of caffeine separated by a 4 hour interval were administered orally. Saliva samples were taken 6 and 14 hours later. Caffeine concentrations were measured by high-performance liquid chromatography. Pharmacokinetic parameters were calculated by the fitting procedure of the Bayesian feedback method. There was a significant increase of caffeine half-life in patients with PBC with the mean (SD) value of 5.47 (1.33) hours as compared to that in healthy controls - 4.5 (0.69) hours. The correlation between the pharmacokinetic parameters of caffeine (half-life, clearance and volume of distribution) was statistically significant (p < 0.05) both with the prothrombin ratio and staging, based on morphologic findings in the PBC group. There was no significant correlation neither between the pharmacokinetic parameters of caffeine and conventional liver function tests, nor between the pharmacokinetic parameters and galactose elimination capacity (GEC). Our results suggest that caffeine clearance, like GEC, quantitates a very particular enzymatic reaction which may not be representative for the functional capacity of the entire organ. Thus, a simplified caffeine clearance test represents a helpful additional criterion for the assessment of hepatic function in patients with PBC.
Keywords: primary biliary cirrhosis, caffeine clearance, Bayesian estimate
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952